Daiichi Sankyo Company, Limited (TSE: 4568)
Health Care · Pharmaceuticals · JP
¥2,829.50
-1.00% today · -23.9% 1Y
Daiichi Sankyo Company, Limited (TSE: 4568) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $32.34B and employs 20,171 people.
Over the last twelve months the share price has lost 23.9%, trading between 2.39K and 4.18K.
Tweenvest scores Daiichi Sankyo Company, Limited across four factors: quality 71/100, value 74/100, growth 64/100, dividend 38/100. Its strongest factor is value.
4568 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $32.34B
- Revenue (TTM)
- $13.68B
- P/E
- 21.45
- EPS
- 131.93
- Dividend yield
- 3.50%
- Beta (5Y)
- -0.18
- 52-week high
- ¥4,178.00
- 52-week low
- ¥2,390.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.82B
- Employees
- 20,171
- Next earnings
- —
About Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
- ISIN
- JP3475350009
- Founded
- 1899
- Listed since
- Sep 28, 2005
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,231.78 | -0.15% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $272.81 | -0.12% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF371.90 | -0.51% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.29 | -1.18% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.